Agnieszka Butwicka
Overview
Explore the profile of Agnieszka Butwicka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
632
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kanina A, Stener-Victorin E, Butwicka A, Oberg A, Rosenqvist M, Cesta C
J Clin Endocrinol Metab
. 2025 Mar;
PMID: 40036632
Aims: Smaller clinical studies report risks of cardiometabolic dysfunction in brothers of women with polycystic ovary syndrome (PCOS). We aim to investigate the risk of adverse cardiometabolic outcomes in men...
2.
Martini M, Kuja-Halkola R, Butwicka A, Du Rietz E, Kanina A, Brikell I, et al.
J Child Psychol Psychiatry
. 2025 Feb;
PMID: 40017336
Background: Autistic individuals often receive psychiatric diagnoses prior to their autism diagnosis. It remains unclear to what extent autistic females and males differ in their likelihood of receiving psychiatric diagnoses...
3.
Kusmierczyk-Koziel H, Michalak A, Chrzanowski J, Blaziak K, Mianowska B, Szadkowska A, et al.
Nord J Psychiatry
. 2025 Jan;
79(2):136-145.
PMID: 39861995
Purpose: Attention-deficit hyperactivity disorder (ADHD) is a common neurodevelopmental condition that affects approximately 5% of the pediatric population, with increased prevalence among those with type 1 diabetes (T1D). Reports suggest...
4.
Dong Z, Zhang L, Li L, Liu S, Brikell I, Kuja-Halkola R, et al.
BMJ Ment Health
. 2024 Sep;
27(1).
PMID: 39322586
Background: Little is known about the impact of cumulative attention-deficit/hyperactivity disorder (ADHD) medication use on the risk of type 2 diabetes (T2D). Objective: The objective is to examine the association...
5.
Bergman D, Roelstraete B, Sun J, Ebrahimi F, Butwicka A, Pardi D, et al.
Am J Gastroenterol
. 2024 Jul;
119(12):2516-2525.
PMID: 38994845
Introduction: Microscopic colitis (MC) is an inflammatory condition of the large intestine. Primarily diagnosed in middle-aged and older adults, the incidence of the disease has increased markedly during the past...
6.
Pahlsson-Notini A, Liu S, Tideman M, Latvala A, Serlachius E, Larsson H, et al.
JCPP Adv
. 2024 Jun;
4(2):e12225.
PMID: 38827981
Background: Evidence for substance use-related problems in individuals with mild intellectual disability is sparse and mainly limited to selected psychiatric populations. We evaluated the risk of substance use-related problems in...
7.
Martini M, Butwicka A, Du Rietz E, Kanina A, Rosenqvist M, Larsson H, et al.
J Child Psychol Psychiatry
. 2024 Jan;
65(9):1135-1144.
PMID: 38239074
Background: Autism and autistic traits onset in childhood but persist into adulthood. Little is known about how genetic and environmental factors influence autism and autistic traits into adulthood. We aimed...
8.
Michalak A, Chrzanowski J, Kusmierczyk-Koziel H, Klejman E, Blaziak K, Mianowska B, et al.
BMJ Open
. 2023 Dec;
13(12):e078112.
PMID: 38086595
Introduction: Attention deficit hyperactivity disorder (ADHD) affects 5%-10% of paediatric population and is reportedly more common in children with type 1 diabetes (T1D), exacerbating its clinical course. Proper treatment of...
9.
Liu S, Lagerberg T, Ludvigsson J, Taylor M, Chang Z, DOnofrio B, et al.
JAMA Netw Open
. 2023 Oct;
6(10):e2336621.
PMID: 37787995
Importance: Children and adolescents with type 1 diabetes (T1D) face elevated risks of psychiatric disorders. Despite their nonnegligible adverse effects, psychotropic medications are a common cost-effective approach to alleviating psychiatric...
10.
Kanina A, Larsson H, Sjolander A, Butwicka A, Taylor M, Martini M, et al.
Transl Psychiatry
. 2023 Sep;
13(1):299.
PMID: 37735153
No abstract available.